Bristol Myers Squibb (CELG-RI) Tax Provisions (2009 - 2026)

Bristol Myers Squibb has disclosed Tax Provisions across 18 years of filings, most recently posting $561.0 million for Q1 2026.

• In Q1 2026, Tax Provisions rose 10.22% year-over-year to $561.0 million; the TTM figure through Mar 2026 stood at $2.3 billion (up 246.35% YoY), while the FY2025 annual figure was $2.3 billion, up 310.11% from the prior year.
• Tax Provisions grew to $561.0 million in Q1 2026, from $384.0 million in the prior quarter.
• Over the last five years, Tax Provisions for CELG-RI reached as high as $919.0 million in Q3 2025 and fell as low as -$398.0 million in Q2 2024.
• The 5-year median for Tax Provisions is $404.0 million (2022), against an average of $303.2 million.
• Annual changes were most pronounced in 2023 — Tax Provisions sank 141.21% — and 2025, when it surged 287.88%.
• A 5-year view of Tax Provisions shows it stood at -$166.0 million in 2022, then surged by 46.99% to -$88.0 million in 2023, then surged by 212.5% to $99.0 million in 2024, then surged by 287.88% to $384.0 million in 2025, then soared by 46.09% to $561.0 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $561.0 million, $384.0 million, and $919.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.